Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUM-191 in Healthy Participants and Bacterial Conjunctivitis
NCT07565103Phase 2Recruiting
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Jun 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitafloxacin in bacterial conjunctivitis (BC), sponsored by Senju Pharmaceutical Co., Ltd.. Started Jun 2026; status: recruiting.
02
Drugs
sitafloxacin
03
Conditions
bacterial conjunctivitis (BC)
Beyond the preview
Go deeper on NCT07565103.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07565103.